Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas

Ain, Kenneth B.; Lee, Charles; Williams, Kathleen

doi:10.1089/thy.2006.0289

Cited by 71 publications

(33 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Daily dose starts at 200 mg and is increased over six weeks to 800 mg or to the maximum tolerated dose (70). The kinase inhibitors and other agents that target vascularity appear to have activity in thyroid cancer that results in partial remission in some patients and stable disease in a large group of patients (approximately 50%).…”

Section: Targeted Therapy In Advanced Thyroid Cancermentioning

confidence: 99%

Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer

Pitoia

Ward

Wohllk

et al. 2009

Arq Bras Endocrinol Metab

127

View full text Add to dashboard Cite

The aims of these recommendations were to develop clinical guidelines for evaluation and management of patients with differentiated thyroid cancer applicable to Latin American countries. The panel was composed by 13 members of the Latin American Thyroid Society (LATS) involved with research and management of thyroid cancer from different medical centers in Latin America. The recommendations were produced on the basis of the expert opinion of the panel with use of principles of Evidence-Based Medicine. Following a group meeting, a first draft based on evidences and the expert opinions of the panel was elaborated and, later, circulated among panel members, for further revision. After, this document was submitted to the LATS members, for commentaries and considerations, and, finally, revised and refined by the authors. The final recommendations presented in this paper represent the state of the art on management of differentiated thyroid cancer applied to all Latin American countries. Arq Bras Endocrinol Metab. 2009;53(7):884-97. KeywordśThyroid cancer; thyroid ultrasonography; radioiodine therapy; thyroglobulin; consensus RESUMO Estas recomendações tiveram por objetivo o desenvolvimento de diretrizes para avaliação e manejo de pacientes com câncer diferenciado da tiroide em países latino-americanos. Um painel composto por 13 membros da Sociedade Latino-Americana de Tireoide (SLAT) -que estavam envolvidos em pesquisas, e eram peritos no cuidado do paciente com câncer da tiroide e provenientes de diferentes centros médicos latino-americanos -utilizou os princípios da Medicina Baseada em Evidências para produzir esse consenso. Após uma primeira reunião, um texto inicial foi elaborado, baseado em evidências e opiniões dos especialistas do painel e, posteriormente, circulado entre os membros do painel, para revisão. Após a revisão, o documento foi enviado aos membros da SLAT para comentários e considerações e, finalmente, revisado e refinado pelos autores. As recomendações finais aqui apresentadas demonstram o estado da arte no manejo do câncer diferenciado da tireoide aplicadas aos países latino-americanos.Arq InTRODUCTIOn T he risk of malignancy in a thyroid nodule varies between 5% and 10% in iodine sufficient countries, and the amount of iodine supplemented in table salt influences on the morphology of the malignant tumor types (1).

show abstract

Section: Targeted Therapy In Advanced Thyroid Cancermentioning

confidence: 99%

Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer

Pitoia

Ward

Wohllk

et al. 2009

Arq Bras Endocrinol Metab

127

View full text Add to dashboard Cite

show abstract

“…Chemotherapy with standard agents (e.g. doxorubicin, cisplatin and taxanes) and thalidomide has not been popular because of unconvincing results with significant toxicity, whereas a newer thalidomide analogue lenalidomide needs to be investigated further [23][24][25][26][27][28]. To summarize, the major issues with these agents have been the requirement for more consistent results from multiple centres that would further validate the initially reported promising results.…”

Section: Diagnostic Investigation Protocol and Interpretive Pitfallsmentioning

confidence: 99%

Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap

Basu

Dandekar

Joshi

et al. 2015

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

One of the most challenging clinical situations in patients with differentiated thyroid cancer (DTC) is an elevated serum thyroglobulin (Tg) level with negative radioiodine scintigraphy (commonly termed BTENIS^). The diagnostic and therapeutic approaches adopted by attending physicians in day-to-day routine vary quite widely. The main reason for this variation is the rarity of the condition (2 -13 % from various series reported in literature), and its management, especially therapeutic strategies, continues to be imperfect in the absence of a clear-cut understanding and lack of evidence of its aetiology, as observed by various authorities [1]. In this editorial, we discuss the different therapeutic strategies that have been explored and the associated pitfalls in interpretation of clinical findings, and propose a logical step-wise algorithmic approach to care to follow in routine clinics in this particular group of patients. Our views are supported by an overview of the evidence in the literature (with respect to both efficacy and adverse effects) and by practical experience. In addition, we critically review and analyse the steps needed in the immediate future to enhance and rationalize patient care. We believe that such endeavours to identify and prioritize the challenges will further the roadmap to the development of a systematic and scientific approach to the management of patients with TENIS.

show abstract

“…Lenalidomide has also been approved for 5q myelodysplastic syndrome. Both agents are under evaluation for the treatment of several solid tumors, including thyroid cancer [65][66][67] and for a range of autoimmune diseases [68].…”

Section: Thalidomide and Lenalidomidementioning

confidence: 99%

Thyroid Function Abnormalities in Patients Receiving Anticancer Agents

Torino¹,

Barnabei²,

Baldelli³

et al. 2012

Thyroid Hormone

View full text Add to dashboard Cite

Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas

Abstract: Thalidomide confers therapeutic benefit in subsets of thyroid cancer patients with rapidly progressive, distantly metastatic disease.

Cited by 71 publications

References 37 publications

Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer

Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer

Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap

Thyroid Function Abnormalities in Patients Receiving Anticancer Agents

Contact Info

Product

Resources

About